Feed BEAM
BEBeam Therapeutics BEAM · NASDAQ
$27.23 -5.58% (-$1.61)
Depth
- Market cap
- $2.98B
- Enterprise value
- $3.01B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 19.1x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -28.6%
- Gross margin
- 18.9%
- Net margin
- -54.7%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 2.20
- Free float
- 85.5%
Sector
Healthcare
Industry
Biotechnology
CEO
John Evans
Employees
540
Headquarters
Cambridge
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Revenue grew by 32% a year over the last 3 years.
- What to watch: Analysts expect revenue to fall by 63% this fiscal year.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What to watch: It passes only 2 of the 9 points of the Piotroski financial health test.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number